PlainRecalls
FDA Drug Low Class III Ongoing

Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50

Reported: October 29, 2025 Initiated: September 12, 2025 #D-0033-2026

Product Description

Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50

Reason for Recall

Tablet/Capsules Imprinted with Wrong ID

Details

Units Affected
13,440 bottles
Distribution
U.S. Nationwide
Location
Mumbai

Frequently Asked Questions

What product was recalled?
Cetirizine Hydrochloride Tablets USP 10 mg, 500 Tablets bottles, Manufactured by: Unique Pharmaceuticals Labs, (A Div. of J.B. Chemicals & Pharmaceuticals, Ltd.), Mumbai 400 030, India. Distributed by: Rising Pharma Holdings, Inc., East Brunswick, NJ 08816, NDC 16571-402-50. Recalled by JB Chemicals and Pharmaceuticals Ltd. Units affected: 13,440 bottles.
Why was this product recalled?
Tablet/Capsules Imprinted with Wrong ID
Which agency issued this recall?
This recall was issued by the FDA Drug on October 29, 2025. Severity: Low. Recall number: D-0033-2026.